Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Aardvark Therapeutics, Inc. (AARD)

NMS · Biotechnology

$6.42-0.27 (-4.04%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$140.5M
P/E (TTM)
EPS
$-3.11
Div Yield
52W Range
$3.35–$17.94
Beta

Company overview

Next earnings: 2026-08-13(16d)

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Peers in Biotechnology

All in industry →

Recent press releases

Aardvark Therapeutics, Inc. has not issued a press release in this window.

SEC filings

All filings →

Aardvark Therapeutics, Inc. has not filed an SEC document in this window.

Aardvark Therapeutics, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
476,595 sh● NEW
784,430 sh+153.5%
50,131 sh-80.2%
483,340 sh+51.2%
717,430 sh+29.1%
297,865 sh+53.5%
97,520 sh● NEW
188,364 sh+94.8%

People at Aardvark Therapeutics, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$9.3M
06/25
NI -$14.4M
09/25
NI -$16.3M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.75
Prior: $-0.66
Revenue sparkline